Trial · NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263, Phase 2, Recruiting, Navy General Hospital, Beijing
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL. Trials, record NCT06503263. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06503263
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
- NCT number
- NCT06503263
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Navy General Hospital, Beijing
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Zanubrutinib plus Lenalidomide as Maintenance Therapy
- First posted
- 2024-07-16
- Last updated
- 2024-09-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | EFS | 2 years | EFS was defined as the time from treatment initiation to progression, relapse, new treatment, or death by any cause, whichever occurred first. |
| Secondary | PFS | 2 years | PFS was defined as the time from study entry until disease progression or death by any cause |
| Secondary | OS | 2 years | OS was defined as the time from treatment initiation to death by any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06503263
GET https://conductscience.org/api/trials/v1/NCT06503263/registered